HC Wainwright Predicts Increased Earnings for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.85) for the quarter, up from their prior estimate of ($0.92). The consensus estimate for Kura Oncology’s current full-year earnings is ($3.23) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($2.16) EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million during the quarter, compared to analyst estimates of $20.16 million.

Other equities research analysts also recently issued research reports about the stock. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. Wedbush boosted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.62.

Kura Oncology Stock Performance

Kura Oncology stock opened at $12.33 on Monday. The firm’s 50 day simple moving average is $10.34 and its 200-day simple moving average is $9.39. The company has a market cap of $1.09 billion, a P/E ratio of -3.66 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. Kura Oncology has a fifty-two week low of $6.95 and a fifty-two week high of $12.85.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Kura Oncology during the 2nd quarter worth about $115,286,000. State Street Corp increased its holdings in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after buying an additional 1,587,959 shares during the last quarter. Bank of America Corp DE acquired a new position in Kura Oncology in the second quarter worth approximately $12,735,000. Jacobs Levy Equity Management Inc. raised its position in Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Kura Oncology in the second quarter valued at approximately $10,927,000.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Troy Edward Wilson acquired 100,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was bought at an average price of $11.12 per share, for a total transaction of $1,112,000.00. Following the purchase, the chief executive officer owned 379,194 shares in the company, valued at approximately $4,216,637.28. This trade represents a 35.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders own 7.60% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.